

Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis

Laurence Poekes¹, Justine Gillard¹, Geoffrey C. Farrell², Yves Horsmans³, Isabelle A. Leclercq¹

¹*Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium*

²*Liver Research Group, Australian National University Medical School at the Canberra Hospital, Canberra, ACT, Australia*

³*Gastroenterology Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium*

Corresponding author: Isabelle A. Leclercq, Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Avenue E Mounier 53, B1.52.01, 1200 Brussels, Belgium, Phone: +32 (0) 2 764 52 73, Fax: +32 (0) 2 764 53 46. Email : isabelle.leclercq@uclouvain.be

Running Title : BAT activation for NASH treatment

Abbreviations: β AR: beta adrenergic receptor; ACC: Acetyl-CoA carboxylase; ACOX: acyl co-A oxidase; AUC: area under the curve; BAT: brown adipose tissue; BMP8b: bone morphogenetic protein 8b; cAMP: cyclic-adenosine monophosphate; cox8b: cytochrome c oxidase subunit VIIIb; CD36: cluster of differentiation 36; Cidea: cell death-inducing DNA fragmentation factor alpha-like effector A; CPT1: Carnitine palmitoyltransferase I; CR: Caloric restriction; DIO2: type II iodothyronine deiodinase; epiAT: epididymal adipose tissue; FAS: Fatty acid synthase; ¹⁸F-FDG-PET CT: 2-désoxy-2-(¹⁸F) fluoro-D-glucose positron emission tomography-computed tomography ; FGF21: fibroblast growth factor 21; GLUT4: glucose transporter type 4; HFD: high-fat diet; ingWAT: inguinal white adipose tissue; LCAD: long-chain acyl-CoA dehydrogenase; LPL: lipoproteine lipase; NAFLD: non-alcoholic fatty liver disease; NAS: Non-alcoholic fatty liver disease Activity Score; NASH: non-alcoholic steatohepatitis; NRG4: neuregulin 4; OGTT: oral glucose tolerance test; PGC1 α : peroxisome proliferator-activated receptor gamma coactivator 1 alpha; PPAR α : peroxisome proliferator-activated receptor alpha; PRDM16: PR domain

containing 16; RT-qPCR: real time quantitative polymerase chain reaction; SCD1: stearoyl-CoA desaturase-1; SH: single housed; SLC25A20: solute carrier family 25 member 20; TMEM26: transmembrane protein 26; TNF α : tumor necrosis factor alpha; UCP1: uncoupling protein-1; WAT: white adipose tissue; WT: wild-type.

Abstract

Non-alcoholic steatohepatitis (NASH) is the form of non-alcoholic fatty liver disease that can evolve to cirrhosis. Lifestyle modifications that achieve 10% weight loss reverse NASH, but there are no effective approved drug treatments. We previously identified defective adaptive thermogenesis as a factor to metabolic contributing syndrome and hepatic steatosis. We have now tested whether increasing non-shivering thermogenesis can improve pre-existing NASH in mice. In high fat diet-fed *foz/foz* mice with established NASH, treatment with β 3AR agonist restored BAT function, decreased body weight, improved glucose tolerance and reduced hepatic lipid content compared to untreated counterparts, but had no impact on liver inflammation or on NAFLD activity score (NAS). Similarly, β 3AR agonist did not alter liver pathology in other steatohepatitis models, including of MCD diet-fed diabetic obese *db/db* mice. Caloric restriction alone alleviated the hepatic inflammatory signature in *foz/foz* mice. Addition of a β 3AR agonist to mice subjected to caloric restriction enhanced weight loss and glucose tolerance and improved liver steatosis, hepatocellular injury and further reduced liver inflammation. These changes contributed to a significantly lower NAS score such no (0/9) animals in this group fulfilled criteria for NASH pathology compared to 8 out of 10 mice under caloric restriction alone. In conclusion, β 3AR agonist counter acts features of the metabolic syndrome and alleviates steatosis, but alone does not reverse NASH. However, when coupled with weight loss therapy, BAT stimulation provides additional therapeutic advantages and reverses NASH.

Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is now the number one cause of liver disease worldwide (1). Its prevalence is increasing, in parallel with obesity and type 2 diabetes (2). The pathological spectrum of NAFLD ranges from simple steatosis to its necro-inflammatory and fibro-progressive form, non-alcoholic steatohepatitis (NASH). Having a NASH greatly increases the risks of cirrhosis, liver failure and hepatocellular carcinoma as well as cardiovascular events thereby raising morbidity and mortality risks (1).

There are currently no approved therapies for NASH. Weight loss remains the most effective weapon (1)(3). Indeed, 5% of weight loss through lifestyle modifications have been shown to decrease liver steatosis while 10% of weight loss significantly improved liver histology (NAFLD activity score (NAS) < 2), including decreased fibrosis among overweight and obese patients with NASH (4). However, only a small proportion of patients can achieve, maintain and sustain this level of weight loss by lifestyle interventions. Bariatric surgery could represent an alternative way to obtain long lasting weight loss but this is a major surgery that also requires extensive lifestyle changes (1). Therefore, there is an interest in investigating alternative or complementary strategies to reverse NASH as a liver disease. Those that improve the metabolic context of NASH (pre-diabetes, established type 2 diabetes, metabolic syndrome) are most attractive for an overall impact on reducing mortality from NAFLD.

There is a correlation between insulin resistance associated with obesity and low brown adipose tissue (BAT) activity. BAT is the main site of non-shivering thermogenesis in mice and humans

(5). In humans, the average BAT mass of a healthy adult is estimated to be around 50 g while BAT aerobic activity contributes 3–5% to basal metabolic rate (6)(7). As an example, in a subject with 63 g of supraclavicular BAT, it was calculated that if the depot was fully activated, it would burn an amount of energy equivalent to 4.1 kg of WAT (or 38,500 Kcal) over the course of a year (6). There is no consensus yet on how to measure BAT. Referring to a recent study (based on CT scan and ^{18}F -labeled fluorodeoxyglucose positron emission tomography/CT (^{18}F -FDG PET/CT), this figure may be underestimated as total BAT has been calculated to amount to 1.5% of the total body mass and 4.3% of the fat mass, with a mean volume of metabolically active BAT of 330ml in lean subjects (8). The stimulation of BAT in human can potentially increase total daily energy expenditure and conceptually represents an adjuvant target to treat obesity. Besides, increasing non-shivering thermogenesis and thereby energy expenditure, induced beneficial effects on insulin resistance and liver steatosis in mice (9–11).

Foz/foz mice are among the few animal models that recapitulates both the metabolic context (metabolic syndrome, metabolic syndrome, obesity) and hepatic characteristics observed in patients with NASH. When fed a high-fat diet (HFD), *foz/foz* mice rapidly develop hepatic complications progressing to severe fibrosing NASH (12,13). We previously reported that obesity, insulin resistance and liver steatosis observed in *foz/foz* mice were the consequences of hyperphagia and low BAT activity, thus pointing out the role of defective BAT thermogenesis in NAFLD pathogenesis. Rescue of BAT capacity via intermittent cold exposure was able to improve glucose tolerance, decrease adiposity and prevent development of liver steatosis (11).

A pharmacologic alternative to cold exposure as a stimulus for non-shivering thermogenesis is beta-3 adrenergic receptor ($\beta 3\text{AR}$) stimulation. In the present study, we investigated whether

increasing thermogenesis with agents such as CL-316,243 and the clinically approved mirabegron could have beneficial effects on NASH. We first demonstrated that chronic treatment effectively enhanced BAT function, corrected metabolic parameters, reduced body weight gain and liver steatosis. In 3 different models of steatohepatitis (2 with associated obesity and diabetes), chronic CL-316,243 treatment had no positive effects on adiposity nor liver pathology. However, when BAT stimulation was coupled with caloric restriction in *foz/foz* mice with pre-established NASH, there was, in addition to improvement of metabolic parameters, a significant decrease in steatosis, hepatocellular injury and hepatic inflammatory signature sufficient to significantly lower NAFLD activity score (NAS) and reverse NASH.

Methods

Animals and diets

The fat Aussie mouse (*foz/foz* mouse) strain on a NOD B10 background was bred and maintained at a constant temperature of 22°C unless otherwise specified, and exposed at all times to a 12-h light/12-h dark cycle. At 5 weeks of age, mice were fed on a high-fat diet (HFD - 60% of calories from fat, 0,03% of cholesterol; Research Diets D12492) provided *ad libitum*.

Six-week-old C57Bl6J and *db/db* mice were purchased from Janvier (France), and maintained in the animal facility of Université catholique de Louvain (Brussels, Belgium). After 2 weeks of acclimatization, C57Bl6 and *db/db* mice were fed a methionine and choline deficient (MCD) diet. At the time of sacrifice, blood was withdrawn by cardiac puncture and organs (liver, white adipose pads and interscapular brown adipose tissues) dissected, weighted, snap frozen in liquid nitrogen and stored at -80°C until analyses or fixed in 4% formalin for histological analyses.

All experiments were performed according to the guidelines for humane care for laboratory animals established by the Université catholique de Louvain in accordance with European regulations, and the study protocol was approved by the university ethics committee (2012/UCL/MD/026; 2016/UCL/MD/003).

Treatments

For β 3AR agonist treatment, (a) mice were implanted an osmotic minipumps (Alzet 1004, Alza, Palo Alto CA) under 1.5% isoflurane and oxygen. The minipumps delivered either PBS or CL-316,243 (daily delivered dose was 1mg/kg body weight) during 4 weeks together with HFD or

MCD. (b) 8wks HFD-*foz/foz* mice received Mirabegron (or vehicle (PBS+10% DMSO) in controls) IP once daily (10mg/Kg).

For caloric restriction (CR) experiment, 8 weeks HFD fed-*foz/foz* mice were transferred in individual cages and received a restricted amount of food (2.5g/day).

Preliminary experiments (not shown) determined that *foz/foz* mice eat a mean of 3.3g HFD/day (17Kcal/day), a 25% decrease in calorie intake (2.5g HFD/day or 13Kcal/day) achieve 10% weight loss upon 2 weeks.

Oral glucose tolerance test.

Glucose (0.063 mg/mouse) was administered by oral gavage to 4-hour fasted animals and glucose levels monitored on tail blood at 0, 15, 30, 60, 90, 120 and 180 min after the gavage using a glucometer (Accuchek). Cumulative area under the curve (AUC) for blood glucose over 180 minutes was calculated.

Cold challenge

HFD-fed *foz/foz* mice were transferred in cages (2 mice per cage) with no bedding and maintained at 4°C for 2h. Body temperature was measured every 2 hours using an electronic thermistor equipped with a rectal probe (Bioseb thermometer TK 8851).

PET/CT imaging

150 μ Ci of 18 F-fluorodeoxyglucose (FDG; Betaplus Pharma, Brussel, Belgium) was injected into the peritoneal cavity and PET/CT scan images acquired 1 hour later using a Gemini PET/CT

system (Philips Healthcare) on anesthetized mice. The PET and CT images were then analyzed with the PMod Software. The interscapular BAT was manually delineated in 3 dimensions. ^{18}F -FDG BAT uptake was expressed as percentage of injected dose per gram of BAT as described previously (11).

Histology and immunohistochemistry

Five μm thick paraffin sections were stained with hematoxylin/eosin and scored for NAS by a blinded examiner according to the system devised for human NASH³⁷. BAT lipid content was quantified using visiopharm software. Uncoupling protein 1 (UCP1), macrophages and neutrophils were detected by IHC using a primary polyclonal rabbit anti-mouse UCP1 Ab (Abcam) with an anti-rabbit streptavidin horseradish peroxidase-conjugated Ab (EnVision; Dako), or rat anti-mouse F4/80 Ab (Abd Serotec MCA497G) or rat anti-mouse Ly6G Ab (BD Pharmingen 551459), followed by a secondary rabbit anti-rat Ab and Anti-rabbit EnVision). Peroxidase activity was revealed with diaminobenzidine (DAB). Quantitative measure of staining intensity and area was obtained using the Leica Tissue IA software.

RNA extraction, reverse transcription, and real-time quantitative polymerase chain reaction

cDNA was synthesized from 1 μg RNA. Gene expression was assessed by quantitative PCR with the Step One Plus device and software (Applied Biosystems, California, USA) using SYBRGreen (Applied Biosystems). mRNA levels were normalized to that of ribosomal protein L19 (RPL19) as a reference gene.

Biochemical analyses

Serum cAMP levels were measured using a direct cAMP ELISA kit (Enzo Life science). NRG4 protein levels in BAT were measured using an ELISA kit (MyBiosource). Total liver lipids were extracted with methanol and chloroform and quantified using the vanillin phosphoric acid reaction³⁸.

Statistics

All data are presented as mean $\pm$ sem. Statistical analyses were performed using a two-tailed Student t-test or one-way ANOVA followed by Bonferroni's post-hoc as appropriate using Graph Pad Prism 7 software. Differences were considered significant at values of $P < 0.05$.

Results

HFD causes NASH and compromises BAT function in *foz/foz* mice.

As also reported elsewhere (12,14,15), *foz/foz* mice fed a HFD for 12 weeks are overtly obese, hyperglycemic and glucose intolerant compared to chow fed (ND; normal diet) littermates (Fig.1A-C). They have exhibit hepatomegaly (Fig.1D) and develop steatohepatitis as indicated by elevated transaminases levels (Fig.1E,F) and liver histology with mean NAS score at 6.6 (range [5-8], noting 8 is the maximum score possible) (Fig.1G). Confirming previous data (11), while having normal base line body temperature (Fig1H) , the phenotype of HFD-fed *foz/foz* mice is associated with defective thermogenesis and poor brown adipose tissue (BAT) function as assessed here by reduced uptake of ^{18}F -FDG substrate upon cold exposure evaluated *in vivo* by PET/CT (Fig1I). The obese, metabolic, thermogenic and hepatic changes were already present after 8 weeks HFD-feeding. Noticeably, there is a worsening of the hepatic phenotype between 8 and 12 weeks with a further decreased BAT activity ($p<0.05$) (Fig1I), elevation of serum transaminase levels ($p<0.001$) (Fig 1E,F) and aggravation of liver pathology (mean NAS score 5.3 at 8weeks vs 6.6 at 12 weeks, $p<0.05$) (Fig 1G).

β 3AR agonists stimulate BAT function in HFD-fed *foz/foz* mice.

To test the effects of a β 3AR agonist treatment on NASH progression, we treated *foz/foz* mice that had been fed the HFD diet for 8 weeks for 4 weeks CL-316,243 (vehicle, PBS to positive controls) via an implanted minipump while the HFD regiment was continued. To assess metabolic changes and evolution of liver pathology we compared the β 3AR- and PBS-treated groups with pre-treatment, 8 weeks HFD-fed mice.

In BAT, CL-316,243 treatment increased cAMP content, the second messenger of the β_3 adrenoreceptor (Fig.2A). This was linked to an enhanced thermogenic program (Fig.2B), evident by induction of expression by a factor 10 of UCP1. This was associated with an increased in UCP1 protein in the tissue as shown by immunohistochemistry (Fig.2C) and confirmed by western blot (Suppl. Fig.2). Beside UCP1 the treatment induced the expression of other BAT genes involved in thermogenesis (PGC1 α and DIO2), lipolysis and in β -oxidation (CPT1B, SLC25A20, ACOX, LCAD, COX8b) and glucose up-take (GLUT4) (Fig.2B). Also, expression levels of BMP8b, shown to increase BAT thermogenesis (Whittle et al., 2012), as well as FGF21 and NRG4, endocrine factors known to have beneficial effects on liver metabolism (16)(17), increased in the BAT of CL-316,243 treated mice (Fig.2B). The molecular signature supports increased thermogenic activity and this was confirmed by a decreased weight and fat content in BAT (Fig.2C,D). CL-316,243 treatment did not associate with changes in body temperature compared to PBS-treated counterpart (suppl.Fig.1). The physiological functionality of BAT was tested by exposing mice at 4°C during 2 hours. Compared to PBS counter-parts that experienced a 5°C drop of their body temperature, CL-316,243 treated HFD-fed *foz/foz* only lost 2°C as the pre-treatment group ($P < 0.05$) (Fig.2E). Under these conditions, glucose uptake by BAT, measured by ^{18}F -FDG PET, was enhanced significantly in CL-316,243 treated mice (Fig.2F). The $\beta_3\text{AR}$ agonist prevented weight gain during the treatment period (Fig.2G) and this was not attributable to a lower food intake as CL-316,243 treated mice consumed at least as much food ($3.3 \pm 0.7\text{g HFD/day/mouse}$) as PBS-treated littermates ($2.8 \pm 0.5\text{ g HFD/day/mouse}$; $p = \text{Not significant}$).

β 3AR agonist treatment improves metabolic syndrome, decreases hepatic fat but does not improve NASH in HFD-fed *foz/foz* mice.

Together with reducing body weight (Fig.2G) CL-316,243 treatment normalized fasting blood glucose levels (Fig.3A) and dramatically improved glucose tolerance (Fig.3B,C). The treatment significantly reduced liver weight (Fig.4A), steatosis, hepatic lipid content (Fig.4B,D) and downregulated genes that mediate lipogenesis (FAS, ACC) while expression of genes involved in β -oxidation were unaffected (Fig.4C). We also observed a decreased TNF α and collagen α 1 gene expression but not of F4/80 and CD68, markers of inflammatory macrophages, nor of α SMA, a marker of hepatic stellate cell activation (Fig.4E). Despite these positive changes at the level of gene expression, there is no effect on transaminases levels (Fig. 4F) or liver pathology, as indicated by the NAS score (Fig. 4G).

β 3AR agonist has no therapeutic effect of non-metabolic steatohepatitis induced by the MCD diet.

We further tested the effect of CL-316,243 treatment and BAT activation on steatohepatitis induced by the MCD diet. To counterbalance the cachectic and catabolic status occurring upon MCD feeding (18) we used obese and diabetic *db/db* mice fed the MCD diet. In such metabolic setting, β 3AR agonist treatment enhanced BAT activity as assessed by decreased BAT weight and fat content (Suppl. Fig. 3A,C), induction of UCP1 gene and protein expression and induction of DIO2 mRNA (Suppl. Fig. 3C,D). Consequent to such activation, treated MCD *db/db* mice better adapted to acute cold exposure (Suppl. Fig. 3B). MCD per se had a dramatic impact on glucose homeostasis, the additional effect of CL-316,243 being only marginal (Suppl. Fig. 3E). In spite,

we saw no change in severity of steatohepatitis with steatosis, inflammation, fibrosis and serum transaminase elevation of similar magnitude between PBS and treated groups (Suppl. Fig. 3F-I). Thus in this model in which steatohepatitis was induced by MCD and thus pathogenically unrelated to obesity and energy substrate overload, β 3AR agonist administration with concomitant high BAT activity had no protective effect on liver pathology.

Coupling BAT stimulation and moderate caloric restriction improves pre-established metabolic syndrome and NASH.

A moderate (10%) body weight is a highly effective strategy for NASH treatment (4,19,20), but long-term maintenance has proven difficult in patients. BAT activation could help maintaining weight loss. To evaluate the effect of such a strategy on NASH, we subjected *foz/foz* mice with pre-established NASH to a moderate caloric restriction combined with a β 3AR agonist treatment or PBS for 4 weeks and compared them with littermates fed ad libitum the HFD, treated with vehicle and single-housed in similar conditions. We titrated caloric restriction to obtain a 10% weight reduction in HFD-fed PBS-treated mice. β 3AR agonist-treated mice received daily the exact same amount of food than PBS-treated mice. Because in mice with food restriction prolonged CL-316,243 administration caused high mortality (5 of 8, not shown), we used in this experiment mirabegron, a well-tolerated and clinically approved β 3AR agonist. At the recommended dose of 10mg/Kg once a day (21), mirabegron potently activated BAT (Suppl. Fig 4.) with no observed adverse effect in chow fed mice.

As targeted, HFD-diet fed *foz/foz* mice subjected to food restriction alone lose 10% of the BW (Fig.5A). This had no effect on BAT weight (0.33 ± 0.07 g versus 0.39 ± 0.04 g in *ad libitum* fed,

single housed controls, NS), fat content (Fig.5B), expression of UCP1 and of other thermogenic genes (Fig.5B,C,D) or on tolerance to cold temperatures (Fig.5E), on fasting blood glucose (Fig.5F), on glucose tolerance (Fig.5G). Mirabegron successfully stimulated BAT and enhanced thermogenic capacities: while base line temperature was unaffected (Suppl Fig.5), it significantly improved cold tolerance (Fig.5E), decreased BAT weight (0.19 ± 0.06 vs 0.33 ± 0.07 in PBS treated, $p < 0.01$) and fat content (Figure Fig.5B). Mirabegron increased UCP1 protein in BAT (Fig.5B,C), upregulated genes involved in thermogenesis (UCP1 and DIO2), β -oxidation (CPT1B, SLC25A20, ACOX, LCAD) and mRNA expression of batokines (BMP8b, adiponectin, FGF21 and NRG4) (Fig.5D). Mirabegron together with food restriction amplified the weight loss to 25% compared to 10% in untreated mice receiving the exact same amount of food (Fig.5A). Increased non-shivering thermogenesis and weight loss in mirabegron-treated mice decreased fasting blood glucose (Fig.5F) and improved glucose tolerance (Fig.5G) compared with mice with caloric restriction alone.

Calorie restriction alone had no significant impact on liver steatosis (Fig.6), liver weight, fat content, or hepatic lipogenesis (Fig.7A-C). By contrast, all those parameters decreased in mice on calorie restriction plus mirabegron treatment. Mirabegron improved steatosis (Fig.6). Reduced liver weight (Fig.6A) and fat content (Fig.6, Fig.7B) likely resulted from the cumulative effect of reduced hepatic lipogenesis (Fig.7C) and increased energy substrate burning in the brown adipose tissue (Fig.5B-D). Restriction of calorie intake was associated with a reduction in transaminase serum levels (Fig. 7F) and in the expression of inflammatory markers F4/80 and CD68 and of pro-inflammatory cytokines in the liver (Fig.7E). We also observed a decreased density of F4/80+ macrophages (Fig 6B) and Ly6G+ neutrophils (Fig.6C) but not in the number

of inflammatory foci as translated by the inflammatory score of 2 similar to that of *ad libitum* fed mice (Fig7G). Superimposition of mirabegron treatment to calorie restriction further decreased liver inflammation as shown by a further reduction in the expression of TNF α and IL1 β (Fig.7E), in the amount of macrophages and recruited neutrophils (Fig.6B,C). Mirabegron decreased transaminase levels (Fig. 7F). Noticeably, a significant lowering of hepatocyte ballooning was also observed in mirabegron treated livers (Fig.7D) as well as in the collagen 1 expression. Cumulatively, the benefit of mirabegron treatment over food restriction alone on steatosis, ballooning and inflammation translates into a significant decrease in NAS score (mean 3.2 ± 1 , range [1-4]) such as none (0/9) of the mirabegron treated mice fulfilled the criteria for NASH versus 5/5 in *ad lib* fed and 5/8 in PBS-food restricted controls ($p < 0.05$) (Fig7G).

Discussion

In the present work, we studied the effects of BAT stimulation using a β 3AR agonist on metabolic and hepatic complications of obesity. In *foz/foz* mice with severe metabolic syndrome, low BAT activity and progressive fibrotic NASH increasing thermogenic capacity via β 3AR agonist treatment improved glucose homeostasis and limited ectopic fat accumulation in the liver. Moreover, when coupled with weight loss therapy, BAT stimulation provides additional therapeutic advantages: it cleared hepatic lipids, reduced hepatocellular injury and inflammation and reverses NASH.

An increasing number of studies support that activation of the thermogenic program in the adipose tissue beneficially impacts on glucose and lipid homeostasis and insulin sensitivity, especially in the context of energy overload and obesity (9,10,22,23). In the HFD-fed *foz/foz* mouse model we used, low thermogenic BAT function accompanies severe insulin resistance and morbid obesity (11). Treatment with β 3AR agonist reactivates BAT and markedly improved glucose homeostasis. NASH is a manifestation of hepatic lipotoxicity in which insulin resistance is a key player. Hence, many studies have investigated whether insulin sensitizers could be a therapeutic option for NASH. Treatment with metformin was not shown to be superior to placebo in ameliorating liver histology in patients with NAFLD (24)(25)(26). Also, while glitazones markedly improve insulin sensitivity, their effects on liver pathology are marginal (27). Here we confirmed that improvement of glucose homeostasis alone obtained by β 3AR agonist-driven BAT activation is not associated with reversal of liver complications, albeit improving steatosis. This adds to the growing evidence that improving insulin sensitivity alone has no therapeutic benefit in NASH management.

Many studies support the importance of lifestyle changes, especially weight loss, on NASH (19). Therefore, weight loss through lifestyle changes is the first line, effective therapy for NASH. The major limitation of weight loss therapy is the difficulty to maintain weight loss over time. Interestingly in our study, when coupled with caloric restriction, BAT stimulation led to additional weight loss, thus supporting increased BAT thermogenesis as an anti-obesity adjuvant option. Cumulatively, the benefit of mirabegron treatment over food restriction alone on steatosis, ballooning and inflammation achieved a reversal of NASH.

Is NASH reversal all due to the magnitude of weight loss? An intensive weight loss program for one year in patients with NASH led to resolution of NASH according to the percentage of weight loss achieved: 26% , 64% and 90% of patients who lost between 5-7 % , 7-10 and >10% of their starting BW resolved NASH (4). In clinical series using bariatric surgery, NASH resolution correlates with the amount of weight loss after surgery (28). Literature in animal models of NASH provides little data except for one study: Larter et al. performed an experiment in which high fat diet fed *foz/foz* mice were reverted to a low fat rodent chow for 12 weeks. Food/calorie consumption was not reported. The regimen attenuated hepatic inflammation and steatosis but did not significantly reduce body weight (-12%) and hepatocellular injury (15). In our hand, quantitative but not qualitative caloric restriction alone that achieved a 10 % weight loss also alleviated molecular inflammatory signature but not steatosis or hepatocellular injury. For ethical reasons, we could not restrict food intake further such as to obtain a 25% body weight loss matching weight loss achieved with moderate food restriction and BAT activation to answer this questions.

Previous reports by us (11) and others (9,29,30) indicate that increasing thermogenic capacities prevent liver steatosis in *ob/ob* and in HFD-fed wild-type or *foz/foz* mice. Here again, we show that in animals with pre-established NASH, activation of the thermogenic program, reduces lipogenesis and significantly limits the accumulation of lipids in the liver. Moderate food restriction causing a 10% weight loss had no such anti-lipogenic effect. A first explanation may involve a shift of lipid flux away from the liver to be used as substrates by the activated BAT (31). Indeed, β 3AR treatment increased expression of LPL, the rate-limiting enzyme for uptake of FFA in BAT as well as it activates the enzymatic machinery for β -oxidation and uncoupling. It also increased glucose uptake (via GLUT4 up-regulation) and consumption, retrieving glucose as a substrate for hepatic lipogenesis. Interestingly, in our experiments, treatment to activate BAT causes a down regulation of hepatic lipogenic genes while the β -oxidative pathway for fat burning remained unchanged. This occurs also upon acute (3 days) administration of mirabegron that activates BAT in chow fed mice (see Suppl. Fig.4). Hepatocytes do not express β 3adrenoreceptor therefore a direct effect is unlikely (32). Therefore, another hypothesis is that BAT activation indirectly decreases lipogenesis and liver lipid storage through secretion of endocrine factors. NRG4, highly enriched in BAT, is a secreted protein which binding to liver receptor regulates *de novo* liver lipid synthesis (17). In humans, NRG4 inversely correlates with liver fat mass (17). In our experiments using 2 different β 3AR agonists (CL-316,243 and mirabegron), decreased hepatic lipogenesis was associated increased NRG4 transcript and protein (Suppl. Fig. 6) in BAT of *foz/foz* mice. Circulating NRG4 levels, which would support distant effect, were however not quantifiable using ELISA tests available. Besides NRG4, other batokines could also positively tune energy homeostasis. For example, engrafted BAT sustains

the secretion of FGF21 and adiponectin, two endocrine factors with metabolic regulatory effects (9,22). In our study, CL-316,243 induced BAT FGF21 by a factor 3 in mice with pre-established NASH but this effect was less in mice under calorie restriction and mirabegron treatment. Further studies will be required to confirm whether and which endocrine factors produced as part of the thermogenic program can act as a negative regulator of lipogenesis in the obese and dysmetabolic context.

In addition to decreased hepatic lipid content, we noted that β 3AR agonists (whether CL-316,243 or mirabegron) lessened hepatocyte ballooning, a likely manifestation of lipotoxicity. Clearance of ballooned hepatocytes was especially noticeable in mice under calorie restriction and mirabegron treatment, a therapeutic regimen particularly efficient in reducing steatosis suggesting that lipid clearance is key to alleviate lipotoxicity.

One of the very interesting findings in the present study is that reduction in quantity (but not quality) of calorie intake for a limited period switches the molecular signature of inflammation in the liver. Food restriction alone significantly decreased F4/80 and CD68 transcripts and proinflammatory cytokines such as TNF or IL1 β , lessened aggregation of inflammatory macrophages and recruitment on neutrophils. Similarly, Larter et al. reported a less inflammatory profile in *foz/foz* mice raised on a HFD and then switched to a carbohydrate rich-fat poor standard rodent chow (15). Addition of a β 3AR agonist to mice subjected to food restriction achieved a significant anti-inflammatory effect in the liver. By contrast, BAT activation alone had no significant impact on hepatic inflammation as shown in HFD-fed *foz/foz* mice or MCD-fed *db/db* mice treated with a β 3AR agonist.

It is now certain that adult humans have appreciable amounts of thermogenic adipose tissue (6,31,32). Obesity associates with decreased functional brown adipose tissue (32) and functional studies performed in a limited number of patients revealed a low BAT activity in subjects with a fatty liver (34). At this stage, it remains unclear as to whether sufficient amounts of active thermogenic adipose tissue are present in NAFLD/NASH patients to exert beneficial therapeutic effects, even when fully activated. There is a tremendous interest in finding strategies to increase the mass and the activity of thermogenic adipose tissue. So far, few clinical trials reported the possibility of stimulating BAT activity in healthy adults through cold exposure or with the β 3AR agonist mirabegron. These short-term studies associated increased BAT activity with an increased resting metabolic rate, whole-body lipolysis, and adipose tissue insulin sensitivity, but not obesity (34)(36)(37)(38). Long term studies in obese subjects, necessary to evaluate impact on body weight, energy balance and metabolic syndrome, are not (yet) available. In the light of our results, it will be interesting to assess BAT and thermogenic capacity in patients with NASH and to test, in those with responsive tissue, if activation of the BAT function helps maintaining body weight loss and brings an additional long-term therapeutic benefit on NASH over life-style change program.

In summary, β 3AR agonist treatment increases adaptive non-shivering thermogenesis, consumption of energy substrates and improve glucose tolerance in morbidly obese mice with metabolic syndrome. While it alleviates partly hepatic fat accumulation and hepatocellular injury, β 3AR agonist treatment alone did not reverse NASH. When coupled with weight loss therapy (here a caloric restriction), β 3AR agonist treatment significantly contributes to a

negative energy balance, improves both metabolic syndrome and NASH. This study provides insights for the potential use of BAT stimulation as an adjuvant therapy for human NASH.

Acknowledgements

The authors thank Natacha Feza-Bingi (UCL, Brussels, Belgium) and Mathilde Beka (UCL, Brussels, Belgium) for animal breeding, genotyping and care; and Anne Bol (UCL, Brussels, Belgium) for PET/CT imaging. The work was financially supported by « Communauté française de Belgique – Actions de Recherche Concertées » (12/17-047) and unrestricted grants from Bristol-Myers Squibb Belgium, MSD Belgium, Gilead Belgium, Janssen Pharmaceutica Belgium and Abbvie Belgium.

Competing financial interests

The authors have no conflict of interest in relation to this work to disclose.

Author contributions

L.P. and I.L. designed the study; L.P. and J.G. performed the experiments and generated the data. L.P. and I.L. analyzed the data and wrote the manuscript; Y.H and G.F. discussed the data and revised the manuscript.

References

1. LaBrecque D.R., Abbas Z., Anania F., et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *J Clin Gastroenterol.* 2014;48:467–73.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther.* 2011;34:274–85.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology.* 2012;55:2005–23.
4. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology.* 2015;149:367–78.e5.
5. Poekes L, Lanthier N, Leclercq IA. Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome. *Clin Sci (Lond).* 2015;129:933–49.
6. Virtanen KA, Lidell ME, Orava J, et al. Functional Brown Adipose Tissue in Healthy Adults. *N Engl J Med.* 2009;360:1518–25.
7. van Marken Lichtenbelt WD, Schrauwen P. Implications of nonshivering thermogenesis for energy balance regulation in humans. *AJP Regul Integr Comp Physiol.* 2011;301:R285–96.
8. Leitner BP, Huang S, Brychta RJ, Duckworth CJ, Baskin AS, McGehee S, et al. Mapping of human brown adipose tissue in lean and obese young men. *Proc Natl Acad Sci.* 2017;114:8649–54.
9. Liu X, Wang S, You Y, et al. Brown adipose tissue transplantation reverses obesity in Ob/Ob mice. *Endocrinology.* 2015;156:2461–9.
10. Yuan X, Wei G, You Y, et al. Rutin ameliorates obesity through brown fat activation. *FASEB J.* 2017;31:333–45.
11. Poekes L, Legry V, Schakman O, et al. Defective adaptive thermogenesis contributes to

- metabolic syndrome and liver steatosis in obese mice. *Clin Sci*. 2017;131:285–96.
12. Larter CZ, Yeh MM, Van Rooyen DM, et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. *J Gastroenterol Hepatol*. 2009;24:1658–68.
 13. Arsov T, Silva DG, O'Bryan MK, et al. Fat aussie--a new Alström syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. *Mol Endocrinol*. 2006;20:1610–22.
 14. Legry V, Van Rooyen DM, Lambert B, et al. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice. *Clin Sci*. 2014;127:507–18.
 15. Larter CZ, Yeh MM, Haigh WG, et al. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease. *Obesity*. 2013;21:1189–99.
 16. Liu J, Xu Y, Hu Y & Wang G. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. *Metabolism*. 2015;64:380–90.
 17. Wang GX, Zhao XY, Meng ZX, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. *Nat Med*. 2014;20:1436–43.
 18. Leclercq IA, Lebrun VA, Stärkel P & Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepatitis: Effect of PPAR γ agonist pioglitazone. *Lab Invest*. 2007;87:56–65.
 19. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol*. 2017;67:829–46.
 20. Marchesini G, Mazzella N, Forlani G. Weight loss for a healthy liver. *Gastroenterology*. 2015;149:274–8.
 21. Calmasini FB, de Oliveira MG, Alexandre EC, et al. Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice. *Neurourol Urodyn*. 2017;36:1511–8.

22. Stanford KI, Middelbeek RJ, Townsend KL, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. *J Clin Invest*. 2013;123:215–23.
23. Hepler C, Shao M, Xia JY, et al. Directing visceral white adipocyte precursors to a thermogenic adipocyte fate improves insulin sensitivity in obese mice. *Elife*. 2017;6:1–33.
24. Haukeland JW, Konopski Z, Eggesbø HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. *Scand J Gastroenterol*. 2009;44:853-60
25. Li Y, Liu L, Wang B, et al. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Biomed Reports*. 2013;1(1):57–64.
26. Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. *Therap Adv Gastroenterol* 2009;2:157–63.
27. Sanyal AJ, Chalasani N, Kowdley K V., et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. *N Engl J Med*. 2010;362:1675–85.
28. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. *Gastroenterology*. 2015;149:379–88.
29. Liu X, Zheng Z, Zhu X, et al. Brown adipose tissue transplantation improves whole-body energy metabolism. *Cell Res*. 2013;23:851–4.
30. Wang H, Liu L, Lin JZ, et al. Browning of White Adipose Tissue with Roscovitine Induces a Distinct Population of UCP1+ Adipocytes. *Cell Metab*. 2016;24:835–47.
31. Bartelt A, Bruns OT, Reimer R, et al. Brown adipose tissue activity controls triglyceride clearance. *Nat Med*. 2011;17:200–6.
32. Ghosh PM, Shu Z-J, Zhu B, et al. Role of b-adrenergic receptors in regulation of hepatic fat accumulation during aging. *J Endocrinol*. 2012;213:251–61.
33. Cypess AM, White AP, Vernochet C, et al. Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat. *Nat Med*. 2013;19:635–9.
34. Yilmaz Y, Ones T, Purnak T, et al. Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans. *Aliment Pharmacol Ther*.

2011;34:318–23.

35. Chondronikola M, Volpi E, Børsheim E, et al. Brown adipose tissue activation is linked to distinct systemic effects on lipid metabolism in humans. *Cell Metab.* 2016;23:1200-1206.
36. Cypess AM, Weiner LS, Roberts-toler C, et al. Activation of human brown adipose tissue by a β 3-adrenergic receptor agonist. *Cell Metab.* 2016;21:33–8.
37. Hibi M, Oishi S, Matsushita M, et al. Brown adipose tissue is involved in diet-induced thermogenesis and whole-body fat utilization in healthy humans. *Int J Obes.* 2016;40:1655–61.
38. Matsushita M, Yoneshiro T, Aita S, et al. Impact of brown adipose tissue on body fatness and glucose metabolism in healthy humans. *Int J Obes (Lond).* 2014;38:812-7.
39. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology.* 2005;41:1313–21.

Figure legends

Figure 1: Under a HFD, *foz/foz* mice become obese, insulin resistant and progressively develop severe NASH.

Body weight (A), fasting blood glucose levels (B), area under the glucose curve during a 180 min glucose tolerance test (C), liver weight (D), serum ALT (E) et AST (F), NAS score according to Kleiner et al. (39)(G) in *foz/foz* mice fed a normal diet for 12 weeks (n=7) or a HFD for 8 (n=6) and 12 weeks (n=10), baseline body temperature (H) and ¹⁸F-Fluorodeoxyglucose uptake by the brown adipose tissue measured by PET/Scan (I - Data are expressed as the percentage of ¹⁸F-FDG injected dose per gram of BAT) in *foz/foz* mice fed a normal diet for 12 weeks (n=5) or a HFD for 8 (n=7) and 12 weeks (n=5). Dot plots indicate values for single mouse, the mean and S.E.M. for each group. One way ANOVA and Bonferroni correction for multiple testing. *p<0.05; **p<0.01; ***p<0.001.

Figure 2: β 3AR agonist CL-316,243 effectively reactivates the BAT in HFD-fed *foz/foz* mice.

After 8 weeks HFD (white bars, n=6)), *foz/foz* mice were implanted a minipump to deliver the β 3AR agonist CL-316,243 (grey bars, n=8) or PBS (black bars, n=8) for 4 weeks, together with HFD. (A) cAMP content in BAT. (B) mRNA expression of genes related to thermogenesis, β -oxidation and batokines in BAT of CL-316,243- and PBS-HFD *foz/foz* mice at the end of the treatment. Data are expressed as fold induction compared to values of the pretreatment (8wk HFD) group. (C) Hematoxylin and eosin staining (upper panels) and immunohistochemical staining of UCP1 (lower panels) in BAT (bar size, 100 μ m). *Foz/foz* mice on a normal diet (ND, standard rodent chow) for the same 12wks duration are controls. (D) BAT weight. (E) Change in

intrarectal temperature change before and after a 2 hours exposure at 4°C. (F) ^{18}F -Fluorodeoxyglucose uptake by interscapular BAT measured by PET/Scan in *foz/foz* mice. Data are expressed as the percentage of ^{18}F -FDG injected dose per gram of BAT. Dotted line in (E) and (F) represents values in controls (*foz/foz* on the ND for 12 wks). (G) body weigh change during the 4 week PBS or CL-316,243 treatment. Results are expressed as mean + S.E.M. for each group. One way ANOVA and Bonferroni correction for multiple testing. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Figure 3: $\beta 3\text{AR}$ agonist CL-316,243 improves glucose homeostasis in HFD-fed *foz/foz* mice

After 8 weeks HFD (white bars; open symbols, $n=6$), *foz/foz* mice were implanted a minipump to deliver the $\beta 3\text{AR}$ agonist CL-316,243 (grey bars; grey symbols, $n=8$) or PBS (black bars, black symbols, $n=8$) for 4 weeks, together with HFD. Fasting blood glucose levels (A). Oral glucose tolerance test: Blood glucose curves (B) and area under the glucose curves (C). Data are represented as mean $\pm$ SEM. Dotted line in (A) and (C) represents values in controls (*foz/foz* on the ND for 12 wks). One-way ANOVA followed by post-hoc Bonferroni analysis. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Figure 4: $\beta 3\text{AR}$ agonist CL-316,243 lessens steatosis in HFD-fed *foz/foz* mice with pre-established NASH

After 8 weeks HFD (white bars, $n=6$), *foz/foz* mice were implanted a minipump to deliver the $\beta 3\text{AR}$ agonist CL-316,243 (grey bars, $n=8$) or PBS (black bars, $n=8$) for 4 weeks, together with

HFD. (A) Liver weight, (B) hepatic lipid content, (C) hepatic mRNA expression of genes involved in lipid metabolism. Data are expressed as fold induction compared to values of the pretreatment (8wk HFD) group. (D) Hematoxylin and eosin staining of liver sections (Original magnification: upper panels 10x and lower panels 20x; bar size: 100µm). Foz/foz mice on a normal diet (ND, standard rodent chow) for the same 12wks duration are controls. (E) hepatic mRNA expression of genes involved in inflammation and fibrosis. Data are expressed as fold induction compared to values of the pretreatment (8wk HFD) group. (F) serum transaminases. Data are represented as mean $\pm$ SEM. One-way ANOVA followed by post-hoc Bonferroni analysis. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. (G) Histological NAS score with in each group the mean steatosis score (white part of the bars), the ballooning score (dotted part of the bars) and the inflammatory score (hatched part of the bars). Dotted line in (A), (B), (F) and (G) represents values in controls (foz/foz on the ND for 12 wks).

Figure 5. Effect of caloric restriction and mirabegron treatment on metabolic parameters and BAT.

After 8 weeks HFD ad libitum, *foz/foz* mice were single housed and randomized on basis of body weight and fasting glycemia in 3 groups receiving either the HFD ad libitum and a daily injection of vehicle (single housed, SH, $n=5$); 2,5g of HFD a day and a daily injection of vehicle (caloric restriction-PBS; CR-PBS, $n=5$) or 2,5g of HFD a day and a daily injection of mirabegron (10mg/kg/d) (CR-M, $n=6$) for 4 weeks. (A) body weight change during the 4 weeks treatment period; (B) Immunohistochemical staining of UCP1 in BAT (bar size, 100µm) and (C) morphometrical quantification of UCP-1 immunostaining; (D) mRNA expression of genes related

to thermogenesis, β -oxidation and batokines in BAT. Data are expressed as fold induction compared to values in *ad libitum*-fed, PBS treated and single housed control group; (E) Change in intrarectal temperature before and after a 2 hours exposure at 4°C; (F) fasting blood glucose levels and (G) area under the glucose curves of the glucose tolerance test performed at the end of the treatment period. Data are mean $\pm$ SEM. One-way ANOVA followed by post-hoc Bonferroni analysis. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; in graph (F): # $p < 0.05$; ## $p < 0.01$; ### $p < 0.001$ for the comparison between SH controls and CR-M and * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ for the comparison between CR-PBS and CR-M.

Figure 6: Effect of calorie restriction and mirabegron treatment on the liver histology

After 8 weeks HFD *ad libitum*, *foz/foz* mice were single housed and randomized on basis of body weight and fasting glycemia in 3 groups receiving either the HFD *ad libitum* and a daily injection of vehicle (single housed, SH, $n=5$); 2,5g of HFD a day and a daily injection of vehicle (calorie restriction-PBS; CR-PBS, $n=5$) or 2,5g of HFD a day and a daily injection of mirabegron (10mg/kg/d) (CR-M, $n=6$). Liver tissues were analyzed after 4 weeks. Foz/foz mice on a normal diet (Chow-fed) for the same 12wks duration are controls. (A) Hematoxylin and eosin staining of liver sections (original magnification X10 upper panels, X20 lower panels ;), (B) F4/80 immunostaining for macrophages and (C) Ly6G immunostaining for neutrophils. In (C) arrows point to isolated neutrophils, while neutrophils aggregates are well identifiable. Bar size, 100 μ m.

Figure 7: Calorie restriction coupled to mirabegron treatment improves NASH.

(A) liver weight; (B) liver lipid content; (C) mRNA expression of genes related to lipogenesis. Data are expressed as fold induction compared to values of *ad libitum*-fed, PBS treated and single housed control group; (D) Ballooning score as per Kleiner et al. (39); (E) mRNA expression of inflammatory genes. Data are expressed as fold induction compared to values of *ad libitum*-fed, PBS treated and single housed control group; (F) Serum alanine aminotransferases levels; (G) Histological NAS score (39) with in each group the mean steatosis score (white part of the bars), the ballooning score (dotted part of the bars) and the inflammatory score (hatched part of the bars). Data are represented as mean $\pm$ SEM. One way ANOVA followed by post-hoc Bonferroni analysis * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

